Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...56789101112131415...3839»
  • ||||||||||  Trial completion date, Trial primary completion date:  Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity (clinicaltrials.gov) -  Jul 8, 2022   
    P4,  N=25, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jul 2021 --> Jul 2023 Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jan 2020 --> Jul 2023
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
    Clinical, Review, Journal:  Children with enthesitis-related arthritis could benefit from treatments targeted for adults with spondyloarthritis. (Pubmed Central) -  Jul 1, 2022   
    Considering the similarities between adult spondyloarthritis and ERA in terms of etiology, genetics, pathogenesis and clinical manifestations summarized in this review, medications approved for axial SpA or peripheral SpA should also be studied in children with active ERA involving axial or peripheral joints, respectively, with the intent to achieve labeling for use in children. Considering the current lack of effective FDA-approved therapies for ERA, the FDA should also consider requiring pediatric studies for medications that have already been approved for the treatment of adults with SpA.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Journal:  Eosinophilic fasciitis induced by certolizumab pegol: association or coincidence? (Pubmed Central) -  Jun 30, 2022   
    Considering the current lack of effective FDA-approved therapies for ERA, the FDA should also consider requiring pediatric studies for medications that have already been approved for the treatment of adults with SpA. No abstract available
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Enrollment closed:  Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) -  Jun 29, 2022   
    P3,  N=193, Active, not recruiting, 
    High quality prospective studies are needed to clarify the validity of these algorithms in the future. Recruiting --> Active, not recruiting
  • ||||||||||  The experience of dual biologic therapy in patients with eosinophilic asthma and autoimmune diseases (TP-10 in thematic poster area) -  Jun 22, 2022 - Abstract #ERS2022ERS_2459;    
    All of them synchronously received mepolizumab for EA and another biologic agent (adalimumab, certolizumab, etanercept, rituximab, or secukinumab) for their AD for different periods with a duration ranging from 6 to 44 months. Preliminary results support that synchronous biologic therapy with different agents in EA and AD is feasible with the conservation of their individual efficacy and the absence of any notable adverse outcomes.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Recurrent psoriatic arthritis involving the temporomandibular joint, successfully treated by adalimumab (e-Poster Hall) -  Jun 13, 2022 - Abstract #EADVSp2022EADV_Sp_457;    
    Patient was suffering last 3 years by nail psoriasis and axial psoriatic arthritis,treated by certolizumab pegol due to secondary failure to brodalumab treatment...Patient underwent complementary treatment with methotrexate 15mg weekly combined with adalimumab in the dosing regimen of 40mg every second week, after the starting dose...Hence collaboration between dermatologist and rheumatologist is very important for early diagnosis of psoriatic arthritis and its exacerbation that can occur with involvement of TMJ. Early biological treatment initiation can both improve the underlying disease and prevent the recurrence such as TMJ involvement, as well.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Zr-89 Cimzia PET Imaging Rheumatoid Arthritis (clinicaltrials.gov) -  Jun 10, 2022   
    P1,  N=10, Suspended, 
    UST and SEC had higher retention rates in comparison with CZP. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  Journal, Adverse events:  Extracellular Vesicles as Innovative Tools for AssessingAdverse Effects of Immunosuppressant Drugs. (Pubmed Central) -  May 29, 2022   
    The meticulous documentation of adverse effects is recommended to further address this question. This review provides relevant information on the links between EVs and immunosuppressive drugs with a focus on EVs' role as tools to assess the effects of immunosuppressants, suggesting innovative properties and new possible therapeutic uses.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Review, Journal:  The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis. (Pubmed Central) -  May 29, 2022   
    Antitumor necrosis factor monoclonal antibodies (except for certolizumab pegol) have been associated with a possible increased risk of preterm birth, low gestational age, and cesarean deliveries. Prospective data on the safety of biologics other than antitumor necrosis factor-alpha antibodies to accurately assess whether novel biologics (eg, anti-interleukin 17, 12/23, 23) can be used for systemic therapy in pregnancy are lacking or currently being conducted.
  • ||||||||||  Review, Journal:  Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis. (Pubmed Central) -  May 29, 2022   
    Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.
  • ||||||||||  Clinical, Retrospective data, Review, Journal:  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) -  May 24, 2022   
    Infliximab, anti-IL17 drugs (bimekizumab, ixekizumab, secukinumab and brodalumab) and anti-IL23 drugs (risankizumab and guselkumab) except tildrakizumab showed a higher proportion of patients reaching PASI 90 than ustekinumab and three anti-TNF alpha agents (adalimumab, certolizumab and etanercept)...No significant difference was shown between apremilast and two non-biological drugs: ciclosporin and methotrexate...Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
  • ||||||||||  INFECTIONS IN PATIENTS WITH RHEUMATIC DISEASES IN TREATMENT WITH BIOLOGIC THERAPY () -  May 24, 2022 - Abstract #EULAR2022EULAR_4369;    
    The frequency of infections in patients using bDMARD in Biobadamex is low compared to the frequency reported in similar studies in other countries 3 . The presence of infections was associated with more severe adverse events in general, which recovered completely without sequels.
  • ||||||||||  COST-MINIMIZATION ANALYSIS IN RHEUMATOID ARTHRITIS IN SPAIN () -  May 24, 2022 - Abstract #EULAR2022EULAR_4322;    
    All the cost information for the therapeutic alternatives (certolizumab, etanercept, golimumab, infliximab, tocilizumab, tofacitinib, and upadacitinib) was gathered from drug cost datasets 7 , and a range of discounts were applied according to experts opinion obtained through a survey. According to our model, ADA was the most cost-effective biologic option for treating RA in Spain, and the sensitivity analysis validated the results.
  • ||||||||||  DIFFERENCES IN THE CLINICAL SPECTRUM OF HAPLOINSUFFICIENCY OF A20 (HA20) CASES DIAGNOSED DURING ADULTHOOD () -  May 24, 2022 - Abstract #EULAR2022EULAR_4232;    
    HA20 can be diagnosed even in adult patients, and the clinical picture of presented cases suggests that monogenic autoinflammatory disorders including HA20 should be suspected in any patient with flares of described manifestations along with strong acute phase response even in adults. Response to corticosteroids and targeted treatments may also be variable.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
    Swollen and tender joints improvement in the randomized controlled trials of psoriatic arthritis () -  May 24, 2022 - Abstract #EULAR2022EULAR_3874;    
    According to a limited number of reports, Anti-TNFs (eg, certolizumab) cause significant improvement in the number of SJ and TJ in the primary endpoint. On the other hand, Ixekizumab has as much effect on SJ and TJ as Adalimumab.
  • ||||||||||  Real-World Treatment Patterns In Patients With Psoriatic Arthritis () -  May 24, 2022 - Abstract #EULAR2022EULAR_3846;    
    Among patients with PsA, there is substantial variability, including high rates of discontinuation within the first year and after index therapy. Further studies are warranted to understand reasons for these treatment patterns.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
    Breastfeeding in women with ankylosing spondylitis (AS) () -  May 24, 2022 - Abstract #EULAR2022EULAR_3787;    
    High AS activity becomes a risk factor for termination of lactation more than 6 months after delivery. It is necessary to conduct training for obstetricians-gynecologists and pediatricians on issues related to medicine capabilities during lactation, in order to exclude unjustified cancellation of medicines compatible with breastfeeding.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
    Association of low trough level of TNFi and their immunogenicity with efficacy in rheumatic diseases and inflammatory bowel diseases () -  May 24, 2022 - Abstract #EULAR2022EULAR_3743;    
    123 patients receiving infliximab (INX) (n=36, 29.3%), adalimumab (ADM) (n=49, 39.8%) and certolizumab pegol (CZP) (n=38, 30.9%) were included into the study. Most of non-responders with RD had either low trough level of TNFi or ADAb, while in IBD group only half of cases of non-response could be attributed to the effect of ADAb or low trough level of TNFi.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
    Comparison of TNF-α inhibitors efficacy between rheumatic diseases and inflammatory bowel diseases () -  May 24, 2022 - Abstract #EULAR2022EULAR_3742;    
    The patients received infliximab (INX, 13 (18.6%) with RD and 23 (43.4%) with IBD), adalimumab (ADM, 36 (51.4%) with RD and 13 (24.5%) with IBD) or certolizumab pegol (CZP, 21 (30%) with RD, 17 (32.1%) with IBD). TNFi are more efficient for the treatment of AS and RA than for IBD (CD and UC).